黑料网

Abstract

Based on the knowledge that sodium intake is positively and potassium intake is negatively associated with blood pressure
level, potassium enriched and sodium reduced salt substitute was developed to replace regular salt in order to lower
blood pressure of the consumers through dietary approach. However, salt substitute has not been widely used in population
although it has been on the market for several decades. This talk will review the evidences from randomized controlled trials
on the efficacy of salt substitute in reducing blood pressure, peripheral and central, and pulse wave velocity as well as the
cardiovascular mortality and total death. Data on its acceptability and possible adverse effects will also be reviewed. Besides,
the talk will cover the effects of strategies that used salt substitute to reduce salt intake. Finally, suggestions will be made on
potential policy implementations.

Biography

Yangfeng Wu after receiving his undergraduate and graduate training in medicine, public health, and epidemiology, started his career as a research fellow in a
US-PRC Collaborative Study of Cardiovascular and Cardiopulmonary Epidemiology at Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical
Sciences. He has led many large scale national and international research projects and published over 200 peer-reviewed papers in Chinese and international
journals. As a cardiovascular expert, he has made valuable contributions to reducing the impact of cardiovascular disease in China, hence received many awards
and honors from Chinese government, non-governmental agencies, and international academic communities.